Wei Dong Liu
Director/Board Member bei TOT BIOPHARM INTERNATIONAL COMPANY LIMITED
Profil
Wei Dong Liu is a non-executive director who currently holds two positions at Tot Biopharm Co. Ltd.
and TOT BIOPHARM International Co. Ltd.
He previously held a non-executive director position at Genetron Holdings Ltd.
Liu earned a doctorate degree from the University of Pittsburgh in 2000 and undergraduate and graduate degrees from Peking University in 1989 and 1994, respectively.
Aktive Positionen von Wei Dong Liu
| Unternehmen | Position | Beginn |
|---|---|---|
| TOT BIOPHARM INTERNATIONAL COMPANY LIMITED | Director/Board Member | 12.08.2023 |
Tot Biopharm Co. Ltd.
 Tot Biopharm Co. Ltd. Pharmaceuticals: MajorHealth Technology Tot Biopharm Co. Ltd. engages in research and development, manufacturing and sales of new drugs. The company was founded on July 5, 2010 and is headquartered in Suzhou, China. | Director/Board Member | 12.08.2023 |
Ehemalige bekannte Positionen von Wei Dong Liu
| Unternehmen | Position | Ende |
|---|---|---|
| GENETRON HOLDINGS LIMITED | Director/Board Member | - |
Ausbildung von Wei Dong Liu
| University of Pittsburgh | Doctorate Degree |
| Peking University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TOT BIOPHARM INTERNATIONAL COMPANY LIMITED | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Tot Biopharm Co. Ltd.
Tot Biopharm Co. Ltd. Pharmaceuticals: MajorHealth Technology Tot Biopharm Co. Ltd. engages in research and development, manufacturing and sales of new drugs. The company was founded on July 5, 2010 and is headquartered in Suzhou, China. | Health Technology |
Genetron Holdings Ltd.
 Genetron Holdings Ltd. Medical/Nursing ServicesHealth Services Genetron Holdings, Ltd. engages in precision oncology. It provides cancer molecular profiling by using technologies in molecular biology and data science to transform cancer treatment. It products and services include diagnosis and monitoring through both LDT and IVD products. Its LDT portfolio consists of both specifically designed focused and comprehensive gene panel testing services. It also develops liver cancer early screening products. The company was founded by Si Zhen Wang, Hai Yan, and Wei Wu He in 2015 and is headquartered in Beijing, China. | Health Services |
